JVM-3 Cells

JVM-3 is a human B-cell prolymphocytic leukemia (B-PLL) cell line established from the peripheral blood of a 73-year-old Caucasian male patient. The line grows in suspension as lymphoblastoid cells either singly or in loose clumps and is a widely used model for B-PLL, a rare and aggressive mature B-cell leukemia. JVM-3 harbors TP53 mutations (p.Pro1435Leu heterozygous and p.Lys601Asn heterozygous), which inactivate the tumor suppressor function of p53 and are associated with resistance to chemotherapy in B-cell malignancies. The line is cultured in 90% RPMI 1640 + 10% heat-inactivated FBS.
JVM-3 is applicable in B-PLL research, including studies of mature B-cell leukemia biology, TP53 mutation-associated drug resistance, BCR signalling pathway analysis, evaluation of targeted therapies (BTK inhibitors, venetoclax, CD20-targeting antibodies), and pharmacological drug screening for B-cell malignancies. It is also used in comparative studies of B-cell leukemia subtypes and as a xenograft model in immunocompromised hosts.